In this video, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly highlights the impact of the recent FDA approval of pemigatinib for the treatment of adult patients with relapsed/refractory (R/R) myeloid/lymphoid neoplasms with FGFR1 rearrangement. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.